| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc96b484de0236a638baa9b5630537bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d07a4ddba85ae3e35ca0a6f85dad9f6d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-22 |
| filingDate |
2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_542d0682f22e3536da3c934a8344a927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3506cb7b87a857a9fd6b93550b71f61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcfeeb27fb597fe33e90e97035c4f93b |
| publicationDate |
2017-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017205963-A1 |
| titleOfInvention |
Mitochondrial pna prostate cancer marker and related systems and methods |
| abstract |
There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1. |
| priorityDate |
2016-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |